Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection.

Literature DB >> 18480233

Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection.

Susan Welkos¹, Sarah Norris, Jeffrey Adamovicz.

Abstract

Defined candidate human vaccines for treating infection by Yersinia pestis, the agent of plague, have been developed. To facilitate evaluation of the vaccines' efficacy, the in vitro caspase-3 assay for cytotoxicity-neutralizing activity was modified and reevaluated. Immune serum-mediated caspase-3 neutralizing activity correlated with protection against infection in a nonhuman primate vaccine model of plague immunity.

Entities: Disease Species

Mesh：

Substances：
Plague Vaccine
Caspase 3

Year: 2008 PMID： 18480233 PMCID： PMC2446635 DOI： 10.1128/CVI.00091-08

Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X

5 in total

Review 1. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Authors: T V Inglesby; D T Dennis; D A Henderson; J G Bartlett; M S Ascher; E Eitzen; A D Fine; A M Friedlander; J Hauer; J F Koerner; M Layton; J McDade; M T Osterholm; T O'Toole; G Parker; T M Perl; P K Russell; M Schoch-Spana; K Tonat
Journal: JAMA Date: 2000-05-03 Impact factor: 56.272

2. Development of in vitro correlate assays of immunity to infection with Yersinia pestis.

Authors: J Bashaw; S Norris; S Weeks; S Trevino; J J Adamovicz; S Welkos
Journal: Clin Vaccine Immunol Date: 2007-03-21

3. A new improved sub-unit vaccine for plague: the basis of protection.

Authors: E D Williamson; S M Eley; K F Griffin; M Green; P Russell; S E Leary; P C Oyston; T Easterbrook; K M Reddin; A Robinson
Journal: FEMS Immunol Med Microbiol Date: 1995-12

4. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.

Authors: D G Heath; G W Anderson; J M Mauro; S L Welkos; G P Andrews; J Adamovicz; A M Friedlander
Journal: Vaccine Date: 1998-07 Impact factor: 3.641

5. Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis.

Authors: S Weeks; J Hill; A Friedlander; S Welkos
Journal: Microb Pathog Date: 2002-05 Impact factor: 3.738

5 in total

10 in total

1. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.

Authors: Jian Sha; Michelle L Kirtley; Curtis Klages; Tatiana E Erova; Maxim Telepnev; Duraisamy Ponnusamy; Eric C Fitts; Wallace B Baze; Satheesh K Sivasubramani; William S Lawrence; Igor Patrikeev; Jennifer E Peel; Jourdan A Andersson; Elena V Kozlova; Bethany L Tiner; Johnny W Peterson; David McWilliams; Snehal Patel; Eric Rothe; Vladimir L Motin; Ashok K Chopra
Journal: Clin Vaccine Immunol Date: 2016-07-05

10. Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.

Authors: Fahreta Hamzabegovic; Johannes B Goll; William F Hooper; Sharon Frey; Casey E Gelber; Getahun Abate
Journal: NPJ Vaccines Date: 2020-01-23 Impact factor: 7.344

10 in total

Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection.

Review 1. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

2. Development of in vitro correlate assays of immunity to infection with Yersinia pestis.

3. A new improved sub-unit vaccine for plague: the basis of protection.

4. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine.

5. Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis.

1. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.

2. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.

3. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague.

4. Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague.

5. Antibodies and cytokines independently protect against pneumonic plague.

6. Pneumonic plague pathogenesis and immunity in Brown Norway rats.

Review 7. Plague vaccines: current developments and future perspectives.

8. The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.

9. Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.

10. Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.